Insiders Updates A Guide To The Risks Of Investing In Syndax Pharmaceuticals Inc (SNDX) Syndax Pharmaceuticals Inc’s filing revealed that its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported $0.11
Stock Earnings Syndax Pharmaceuticals Inc (SNDX) may enjoy gains as insiders got busy in the recent days In a filing, Syndax Pharmaceuticals Inc revealed its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported
Insiders Updates Syndax Pharmaceuticals Inc [SNDX] Records 200-Day SMA of $15.92 Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Featured Why Syndax Pharmaceuticals Inc. (SNDX) stock is decreasing rapidly? Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer